Stay updated on Nivolumab for Relapsed Pediatric Solid Tumors Clinical Trial
Sign up to get notified when there's something new on the Nivolumab for Relapsed Pediatric Solid Tumors Clinical Trial page.
Latest updates to the Nivolumab for Relapsed Pediatric Solid Tumors Clinical Trial page
- Check5 days agoChange DetectedRevision updated from v3.3.3 to v3.3.4; no visible changes to study details or eligibility criteria. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%
- Check12 days agoNo Change Detected
- Check19 days agoNo Change Detected
- Check26 days agoChange DetectedFooter now displays Revision: v3.3.3; the items HHS Vulnerability Disclosure and Revision: v3.3.2 have been removed.SummaryDifference0.1%
- Check55 days agoChange DetectedThe page shows a revision update from v3.2.0 to v3.3.2, indicating a minor site maintenance update that does not alter study details, eligibility, outcomes, or contacts. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%
- Check62 days agoChange DetectedThe government funding lapse notice banner has been removed from the page.SummaryDifference0.4%
- Check76 days agoChange DetectedThe new screenshots show only minor visual and layout updates to the Study Details page, with no changes to core study information such as eligibility criteria, endpoints, or enrollment. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%
- Check105 days agoChange DetectedUpdated the page to v3.2.0 with a prominent notice about potential data/tansaction delays due to funding gaps and where to check operating status; previous v3.1.0 reference removed.SummaryDifference4%
Stay in the know with updates to Nivolumab for Relapsed Pediatric Solid Tumors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab for Relapsed Pediatric Solid Tumors Clinical Trial page.